Effect of Rapamycin in Women with Diminished Ovarian Reverse: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300069828

Enrollment

Unknown

Registered

2023-03-27

Start date

2023-04-01

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished Ovarian Reverse

Interventions

research group :Rapamycin is taken orally

control group:conventional IVF procedure

Eligibility

Sex/Gender

Female

Age

25 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) The number of follicles in bilateral ovaries was less than 6; AMH 15U/L; (2) The number of eggs obtained =5; (3) Not pregnant after one more time IVF-ET.

Exclusion criteria

Exclusion criteria: (1) Patients with a history of sexually transmitted diseases, genetic diseases, uterine malformations, and endometriosis cysts; (2) male oligospermia or anspermia; (3) Allergic to rapamycin and its derivatives; (4) serious other systemic diseases.

Design outcomes

Primary

Measure	Time frame
Anti-mullerian hormone;Basal follicle number;No. of follicle retrieved;Embryo number;	—

Secondary

Measure	Time frame
follicle-stimulating hormone;rate of pregnancy;live birth rate;granular cell;	—

Countries

China

Contacts

Public ContactTao Yang

Shanxi Medical University

yangtao056cn@sxmu.edu.cn18734892997

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026